Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.provenanceCONICET-
dc.creatorGarcia Bustos, Maria Fernanda-
dc.creatorBarrio, Alejandra-
dc.creatorPrieto, Gabriela G.-
dc.creatorDe Raspi, Emma M.-
dc.creatorCimino, Rubén Oscar-
dc.creatorCardozo, Rubén Marino-
dc.creatorParada, Luis Antonio-
dc.creatorYeo, Matthew-
dc.creatorSoto, Jaime-
dc.creatorUncos, Delfor Alejandro-
dc.creatorParodi Ramoneda, Cecilia María-
dc.creatorBasombrío, Miguel Ángel Manuel-
dc.date2018-02-26T19:03:33Z-
dc.date2018-02-26T19:03:33Z-
dc.date2014-12-
dc.date2018-02-26T15:08:18Z-
dc.date.accessioned2019-04-29T15:37:08Z-
dc.date.available2019-04-29T15:37:08Z-
dc.date.issued2014-12-
dc.identifierGarcia Bustos, Maria Fernanda; Barrio, Alejandra; Prieto, Gabriela G.; De Raspi, Emma M.; Cimino, Rubén Oscar; et al.; In vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis; American Society of Parasitologists; Journal of Parasitology; 100; 6; 12-2014; 840-847-
dc.identifier0022-3395-
dc.identifierhttp://hdl.handle.net/11336/37136-
dc.identifierCONICET Digital-
dc.identifierCONICET-
dc.identifier.urihttp://rodna.bn.gov.ar:8080/jspui/handle/bnmm/297848-
dc.descriptionLeishmaniasis, a disease caused by parasites of the Leishmania genus, constitutes a significant health and social problem in many countries and is increasing worldwide. The conventional treatment, meglumine antimoniate (MA), presents numerous disadvantages, including invasiveness, toxicity, and frequent therapeutic failure, justifying the attempts at finding alternatives to the first-line therapy. We have studied the comparative long-term efficacy of MA against miltefosine (MF) in Leishmania infection in experimental mice. The criteria for efficacy evaluation were footpad lesion size, anti-Leishmania antibodies level, histopathology of the site of inoculation (right footpad, RFP), splenic index (SI), and the presence of parasites in RFP, spleen, and liver, determined by polymerase chain reaction (PCR). Swiss mice, infected with Leishmania (Leishmania) amazonensis were treated, at different time points (5 and 40 days after infection) with either MA or MF. The efficacy of MF was better than that of MA for inhibiting lesions and for reducing tissue damage and presence/load of amastigotes in spleen and liver. Moreover, early administration of MF produced a clear reduction in splenomegaly and was equal in reducing antibody titles in comparison with MA. Our results demonstrated that MF is an effective and safe therapeutic alternative for leishmaniasis by L. (L.) amazonensis and is more efficacious than MA.-
dc.descriptionFil: Garcia Bustos, Maria Fernanda. Universidad Nacional de Salta; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina-
dc.descriptionFil: Barrio, Alejandra. Universidad Nacional de Salta; Argentina-
dc.descriptionFil: Prieto, Gabriela G.. Universidad Nacional de Salta; Argentina-
dc.descriptionFil: De Raspi, Emma M.. Universidad Nacional de Salta; Argentina-
dc.descriptionFil: Cimino, Rubén Oscar. Universidad Nacional de Salta; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina-
dc.descriptionFil: Cardozo, Rubén Marino. Universidad Nacional de Salta; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina-
dc.descriptionFil: Parada, Luis Antonio. Universidad Nacional de Salta; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina-
dc.descriptionFil: Yeo, Matthew. London School of Hygiene and Tropical Medicine; Reino Unido-
dc.descriptionFil: Soto, Jaime. Universidad Nacional de Salta; Argentina. Fundación FADER; Colombia-
dc.descriptionFil: Uncos, Delfor Alejandro. Universidad Nacional de Salta; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina-
dc.descriptionFil: Parodi Ramoneda, Cecilia María. Universidad Nacional de Salta; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina-
dc.descriptionFil: Basombrío, Miguel Ángel Manuel. Universidad Nacional de Salta; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina-
dc.formatapplication/pdf-
dc.formatapplication/pdf-
dc.formatapplication/pdf-
dc.formatapplication/pdf-
dc.formatapplication/pdf-
dc.languageeng-
dc.publisherAmerican Society of Parasitologists-
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1645/13-376.1-
dc.relationinfo:eu-repo/semantics/altIdentifier/url/http://www.bioone.org/doi/abs/10.1645/13-376.1-
dc.rightsinfo:eu-repo/semantics/restrictedAccess-
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/-
dc.sourcereponame:CONICET Digital (CONICET)-
dc.sourceinstname:Consejo Nacional de Investigaciones Científicas y Técnicas-
dc.sourceinstacron:CONICET-
dc.source.urihttp://hdl.handle.net/11336/37136-
dc.subjectMILTEFOSINE-
dc.subjectLEISHMANIA-
dc.subjectAMAZONENSIS-
dc.subjectEFFICACY-
dc.subjectSalud Ocupacional-
dc.subjectCiencias de la Salud-
dc.subjectCIENCIAS MÉDICAS Y DE LA SALUD-
dc.titleIn vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.typeinfo:ar-repo/semantics/articulo-
Aparece en las colecciones: CONICET

Ficheros en este ítem:
No hay ficheros asociados a este ítem.